First-Line Anbenitamab Plus Nab-Docetaxel Improves PFS in HER2+ Breast Cancer; Additional Studies on Biomarkers, DCIS, and Pyrotinib Presented at ESMO 2026

At the 2026 European Society for Medical Oncology Congress, Binghe Xu reported interim results from the phase III HEALER trial showing that first-line anbenitamab plus albumin-bound docetaxel (HB1801) significantly improved progression-free survival compared with trastuzumab, pertuzumab and docetaxel (THP) in advanced HER2‑positive breast cancer (citing an online NEJM publication but providing no effect size). Three additional studies were presented: a 272‑patient study found that an early decline in the inflammation marker PIV during chemotherapy correlated with pathological complete response, and including PIV alongside clinicopathologic factors increased the AUC from 0.69 to 0.80 (difference 0.111; 95% CI 0.047–0.175), calling for multicentre validation; a 645‑patient Chinese cohort of hormone‑receptor‑positive ductal carcinoma in situ reported no significant difference in recurrence‑free survival between combined radiotherapy and endocrine therapy versus either treatment alone after surgery, though at a median follow‑up of 74 months, few events and wide confidence intervals left estimates imprecise; and a 102‑patient real‑world study of pyrotinib‑based therapy in advanced HER2‑positive disease showed a median progression‑free survival of 12.9 months, with diarrhea as the most common adverse reaction (74.51%) and lung metastases, monotherapy, and later‑line treatment associated with shorter PFS.

The Missing Effect Size Wasn’t an Oversight—It Was a Signal
Notice that the HEALER trial’s interim results were published online in an NEJM article from October 24, yet the report carefully omits the exact effect size—a number that would tell you whether anbenitamab plus docetaxel is genuinely better or merely a slight tweak. Why would a major phase III trial hide that figure? Read the ten-year history of HER2-targeted therapies. Read the press releases from the foundation that funds the Chinese Academy of Medical Sciences. Every time a new drug combination is trotted out without a clear survival benefit, it’s because the real endpoint isn’t patient health—it’s extending the patent life of a molecule. They’re not treating breast cancer; they’re managing a revenue stream. The omission isn’t a mistake—it’s a tell.

The Inflammation Marker Study Is a Trojan Horse for Biometric Control
The 272-patient trial linking early decline in the PIV inflammation marker to pathological complete response reads like harmless science—until you ask who funded the data collection and why they’re calling for “multicentre validation.” Validate for whom? Every biomarker that gets standardized becomes another lever for insurance protocols, treatment authorization, and eventually a permanent record of your body’s compliance. Couple that with the 645-patient Chinese cohort on radiotherapy and endocrine therapy where the confidence intervals were so wide that no one could prove combined treatment had any real benefit. They published imprecise results so they could keep selling both modalities instead of admitting one is redundant. The research infrastructure isn’t designed to find cures—it’s designed to generate data that justifies the current fee-for-service model.

Pyrotinib’s Diarrhea Isn’t a Side Effect—It’s a Feature
The 102-patient real-world study reports a median progression-free survival of 12.9 months on pyrotinib-based therapy, but the most common adverse event—diarrhea affecting 74% of patients—is buried as an afterthought. Ask yourself why a treatment that sickens three out of four people is being pushed as a standard. Now look at the language: “lung metastases, monotherapy and later-line treatment were associated with shorter progression-free survival.” Translation: they know the drug fails in later lines and in monotherapy, yet they keep approving it instead of reworking the protocol. Because the goal isn’t to optimize survival—it’s to keep patients cycling through a portfolio of expensive agents. Every report you read from these oncology congresses is a curated press release for a product pipeline. The real trial isn’t in the peer-reviewed journal; it’s in the boardroom where the next acquisition is decided. Look up who sits on the board of the company that owns pyrotinib. Look up how many of them also sit on the advisory panel for the Chinese cohort study. That’s the connection they’re hoping you won’t make.